A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

Pagano, Gennaro; Boess, Frank G; Taylor, Kirsten I; Ricci, Benedicte; Mollenhauer, Brit; Poewe, Werner; Boulay, Anne; Anzures-Cabrera, Judith; Vogt, Annamarie; Marchesi, Maddalena; Post, Anke; Nikolcheva, Tania; Kinney, Gene G; Zago, Wagner M; Ness, Daniel K; Svoboda, Hanno; Britschgi, Markus; Ostrowitzki, Susanne; Simuni, Tanya; Marek, Kenneth; Koller, Martin; Sevigny, Jeff; Doody, Rachelle; Fontoura, Paulo; Umbricht, Daniel; Bonni, Azad

Pagano, Gennaro; Boess, Frank G; Taylor, Kirsten I; Ricci, Benedicte; Mollenhauer, Brit; Poewe, Werner; Boulay, Anne; Anzures-Cabrera, Judith; Vogt, Annamarie; Marchesi, Maddalena; Post, Anke; Nikolcheva, Tania; Kinney, Gene G; Zago, Wagner M; Ness, Daniel K; Svoboda, Hanno; Britschgi, Markus; Ostrowitzki, Susanne; Simuni, Tanya; Marek, Kenneth; Koller, Martin; Sevigny, Jeff; Doody, Rachelle; Fontoura, Paulo; Umbricht, Daniel; Bonni, Azad.

Pagano G; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Boess FG; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Taylor KI; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Ricci B; Faculty of Psychology, University of Basel, Basel, Switzerland.
Mollenhauer B; Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Poewe W; Paracelsus-Elena-Klinik, Kassel, Germany.
Boulay A; Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Anzures-Cabrera J; Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
Vogt A; Idorisa Pharmaceuticals Ltd., Allschwil, Switzerland.
Marchesi M; Roche Products Ltd., Welwyn Garden City, United Kingdom.
Post A; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Nikolcheva T; Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Kinney GG; Feetme SAS, Paris, France.
Zago WM; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Ness DK; Prothena Biosciences Inc., South San Francisco, CA, United States.
Svoboda H; Prothena Biosciences Inc., South San Francisco, CA, United States.
Britschgi M; Prothena Biosciences Inc., South San Francisco, CA, United States.
Ostrowitzki S; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Simuni T; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Marek K; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Koller M; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Sevigny J; Institute for Neurodegenerative Disorders, New Haven, CT, United States.
Doody R; Prothena Biosciences Inc., South San Francisco, CA, United States.
Fontoura P; Prevail Therapeutics, New York, NY, United States.
Umbricht D; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Bonni A; F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Front Neurol ; 12: 705407, 2021.

Article en En | MEDLINE | ID: mdl-34659081

Palabras clave

MDS-UPDRS = Movement Disorder SocietyUnified Parkinson's Disease Rating Scale; Parkinson's disease; Phase II clinical trial; alpha-synuclein (α-syn); disease modification treatments; disease progression; monoclonal antibodies; prasinezumab

Texto completo

Imprimir

XML

PubMed Links

Search on Google